LON:SLNSilence Therapeutics Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 437 -21.00 (-4.59 %) (As of 06/5/2020 06:24 AM ET) Add Compare Share Today's Range 434.17Now: GBX 437▼ 462.2750-Day Range 363MA: GBX 424.76▼ 48352-Week Range 42Now: GBX 437▼ 646.50Volume10,583 shsAverage Volume13,380 shsMarket Capitalization£361.82 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 605, Silence Therapeutics has a potential upside of 38.4% from its current price of GBX 437.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSilence Therapeutics has received 200 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSilence Therapeutics has received 181 “underperform” votes. (Add your “underperform” vote.)Community SentimentSilence Therapeutics has received 52.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Silence Therapeutics and other stocks. Vote “Outperform” if you believe SLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SLN will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have sold 383.94% more of their company's stock than they have bought. Specifically, they have bought £74,260 in company stock and sold £359,376.94 in company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from GBX (17.88) to GBX 0 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -17.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -17.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 16.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.35 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SLN Previous Symbol CUSIPN/A CIKN/A Webwww.silence-therapeutics.com Phone+44-20-34576900Debt Debt-to-Equity Ratio1.37 Current Ratio3.88 Quick Ratio3.84Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales£244,000.00 Price / Sales1,482.87 Cash FlowGBX 41.29 per share Price / Cash Flow10.58 Book ValueGBX 26.70 per share Price / Book16.37Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares82,796,304Market Cap£361.82 million Next Earnings DateN/A OptionableNot Optionable LSE:SLN Rates by TradingView Receive SLN News and Ratings via Email Sign-up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Silence Therapeutics (LON:SLN) Frequently Asked Questions How has Silence Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Silence Therapeutics' stock was trading at GBX 470 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SLN shares have decreased by 7.0% and is now trading at GBX 437. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Silence Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Silence Therapeutics. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (LON:SLN) posted its earnings results on Tuesday, September, 11th. The company reported ($12.40) earnings per share (EPS) for the quarter. View Silence Therapeutics' earnings history. What price target have analysts set for SLN? 1 equities research analysts have issued 12-month price objectives for Silence Therapeutics' stock. Their forecasts range from GBX 605 to GBX 605. On average, they anticipate Silence Therapeutics' stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 38.4% from the stock's current price. View analysts' price targets for Silence Therapeutics. Has Silence Therapeutics been receiving favorable news coverage? Media stories about SLN stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Silence Therapeutics earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View the latest news aboutSilence Therapeutics. Who are some of Silence Therapeutics' key competitors? Some companies that are related to Silence Therapeutics include NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL), Aptose Biosciences (APS), PureTech Health (PRTC), Bellus Health (BLU), Oxford BioMedica (OXB), CEL-SCI (CVM), Cel-Sci (CVM), SIGA Technologies (SIGA), Paradigm Biopharmaceuticals (PAR), Biotest (BIO) and Neptune Wellness Solutions (NEPT). View all competitors. What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), ANCHIANO THERAP/S (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA). Who are Silence Therapeutics' key executives? Silence Therapeutics' management team includes the following people: Dr. David Horn Solomon, CEO & Director (Age 59)Dr. Rob Quinn, Chief Financial OfficerDr. Mark Cameron, Head of ChemistryMr. Richard Jenkins, Head of Clinical Devel. What is Silence Therapeutics' stock symbol? Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN." How do I buy shares of Silence Therapeutics? Shares of SLN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Silence Therapeutics' stock price today? One share of SLN stock can currently be purchased for approximately GBX 437. How big of a company is Silence Therapeutics? Silence Therapeutics has a market capitalization of £361.82 million and generates £244,000.00 in revenue each year. What is Silence Therapeutics' official website? The official website for Silence Therapeutics is www.silence-therapeutics.com. How can I contact Silence Therapeutics? Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The company can be reached via phone at +44-20-34576900. This page was last updated on 6/5/2020 by MarketBeat.com Staff
